NeuroOne Medical Technologies (NASDAQ:NMTC) Stock Price Down 1.8% – Here’s What Happened

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC)’s share price was down 1.8% during mid-day trading on Monday . The stock traded as low as $0.67 and last traded at $0.6771. Approximately 66,753 shares were traded during trading, a decline of 67% from the average daily volume of 204,356 shares. The stock had previously closed at $0.6894.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Maxim Group started coverage on NeuroOne Medical Technologies in a report on Tuesday, September 9th. They set a “buy” rating and a $3.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “hold” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, NeuroOne Medical Technologies has a consensus rating of “Hold” and an average price target of $2.23.

NeuroOne Medical Technologies Price Performance

The firm has a market capitalization of $31.51 million, a P/E ratio of -4.20 and a beta of 0.70. The company’s 50 day moving average price is $0.85 and its 200 day moving average price is $0.76.

Hedge Funds Weigh In On NeuroOne Medical Technologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sio Capital Management LLC acquired a new stake in shares of NeuroOne Medical Technologies during the second quarter worth $2,390,000. Vanguard Group Inc. lifted its stake in NeuroOne Medical Technologies by 31.2% in the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after buying an additional 375,639 shares during the period. Virtu Financial LLC bought a new position in NeuroOne Medical Technologies during the third quarter worth about $88,000. Goldman Sachs Group Inc. acquired a new position in shares of NeuroOne Medical Technologies during the 1st quarter worth about $84,000. Finally, XTX Topco Ltd bought a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter valued at about $51,000. 16.07% of the stock is owned by institutional investors.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.